Researchers and regulators reflect on first gene therapy death

Article Abstract:

Issues discussed concern the US National Institutes of Health's and the the Recombinant DNA Advisory Committee's investigation into the death of a person involved in gene therapy trials. Topics addressed include adenovirus-based gene therapy, and guidelines for reporting negative consequences of clinical trials.

User Contributions:

Comment about this article or add new information about this topic:

Comment:  (50-4000 characters)

Name:

E-mail:

Security Code:

NIH researchers receive cut-price BRCA test

Article Abstract:

This article discusses the agreement between Myriad Genetic Laboratories and the National Institutes of Health over the costs of cancer susceptible genes BRCA1 and BRCA2. The company owns the patents on the breast and ovarian cancer causing genes, and has agreed to sell them to the institute at reduced rate, as long as they are used for research.

User Contributions:

Comment about this article or add new information about this topic:

Comment:  (50-4000 characters)

Name:

E-mail:

Security Code:

EMSY, a BRCA-2 partner in crime

Article Abstract:

The identification of EMSY, a binding partner for BRAC 2 bolsters the finding that sporadic breast cancers rarely have BRCA 2 or BRCA 1 mutations. The BRAC-2/EMSY complex formation facilitates sporadic breast cancer.

User Contributions:

Comment about this article or add new information about this topic:

Comment:  (50-4000 characters)

Name:

E-mail:

Security Code: